KCSA Psychedelics Conference. Wednesday, October 13th.

October 11, 2021

The KCSA Psychedelics Conference features live presentations and speakers who will address the various investment opportunities in psychedelic treatments for mental health disorders.

The agenda highlights companies representing research, drug development, patient care delivery, integrated technology solutions, and patient support services that are crucial components of the reemerging psychedelic industry.

Presenting companies include a variety of business models including drug developers, investment funds, care delivery treatment clinics, cGMP operators, and vertically integrated business models.

October 13th Agenda

9:45 AM ET

KCSA Opening Remarks

10:00 AM ET

Small Pharma Inc.

TSX-V: DMT
Peter Rands, CEO
Dr Carol Routledge, Chief Scientific and Medical Officer

10:30 AM ET

Awakn Life Sciences Corp.

OTCQB: AWKNF | NEO: AWKN
Anthony Tennyson, CEO

11:00 AM ET

HMNC Brain Health

Private Company
Benedikt von Braunmühl, CEO
Maximilian Döbler, Head of Operations

11:30 AM ET

Enveric Biosciences

NASDAQ: ENVB
Joseph Tucker, CEO

12:00 PM ET

Mind Cure Health Inc.

OTCQX: MCURF | CSE: MCUR
Kelsey Ramsden, President & CEO

12:30 PM ET

Field Trip Health Ltd.

NASDAQ: FTRP | TSX: FTRP
Joseph del Moral, Co-Founder & CEO

1:00 PM ET

Novamind Inc.

OTCQB: NVMDF | CSE: NM
Yaron Conforti, CEO, Director, Co-Founder

1:30 PM ET

BetterLife Pharma Inc.

OTCQB: BETRF | CSE: BETR
Ahmad Doroudian, CEO & Director

2:00 PM ET

MYND Life Sciences Inc.

Pink: MYNDF | CSE: MYND
Dr. Lyle Oberg, CEO

October 14th Agenda

9:50 AM ET

KCSA Opening Remarks

10:00 AM ET

Mindset Pharma Inc.

OTCQB: MSSTF | CSE: MSET
James Lanthier, CEO

10:30 AM ET

PsyBio Therapeutics Corp.

OTCQB: PSYBF | TSX-V: PSYB
Evan Levine, Co-Founder, CEO and Director

11:00 AM ET

Psyched Wellness Ltd.

OTCQB: PSYCF | CSE: PSYC
Jeff Stevens, CEO

11:30 AM ET

Bright Minds Biosciences Inc.

OTCQB: BMBIF | CSE: DRUG
Ian McDonald, President & CEO
Josh Blacher, VP of Corporation Development

12:00 PM ET

Fireside Chat

Amy Emerson, CEO, MAPS Public Benefit Corp
Moderated by Tim Regan, SVP, KCSA Strategic Communications

12:30 PM ET

Lunch Panel – Investing in Psychedelics and CNS Treatments

Lindsay Hoover, Partner, JLS Fund
Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL),
AdvisorShares Investments
Moderated by Tim Regan, SVP, KCSA Strategic Communications

1:00 PM ET